SecBot SecBot

BIOA

BioAge Labs, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001709941 Biotech & Drug Discovery
$5.22 −0.33 (−5.95%)
Nov 16 4:00 PM ET · prev $5.55
Market cap
$259.7M
Micro cap
Consensus
Buy
75% Buy or better · 16 analysts
Median target
$25.00
+379% · range $8.00–50.00
Next earnings
Nov 25
in 9 days · EPS est. −$0.73
1 year
−37.2%
from $8.31 · Nov 17
30 days
+7.9%
from $4.84
52-week range
$4.84–25.10
−79% from high · low Oct 16
Avg volume 20D
702.4K
shares / day
Short interest
3.73M
≈8.1% of shares · +8.6%
Days to cover
4.3
at average volume
Insider net
−$2.0M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 25, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.0M.

  • InstitutionsBULLISH

    Q2 2026: 33 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    12 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.629 → −$0.731 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +8.6% to 3.73M shares. 4.3 days to cover, ≈8.1% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD2,849,077$69.8M
GEODE CAPITAL MANAGEMENT, LLCADD1,004,264$24.6M
BALYASNY ASSET MANAGEMENT L.P.TRIM702,858$17.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD410,165$10.1M
DIMENSIONAL FUND ADVISORS LPADD394,138$9.7M
Walleye Capital LLCDOUBLED354,395$8.7M
Nuveen, LLCDOUBLED349,142$8.6M
NORTHERN TRUST CORPADD343,166$8.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 75% rate it Buy or better
Strong Buy6Buy6Hold4Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +379%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 9, 2026BTIG
REITERATE
REITERATEBuy
Oct 12, 2026UBS
INITIATE
INITIATENeutral
Sep 9, 2026Roth Capital
REITERATE
REITERATEBuy
Sep 8, 2026BTIG
REITERATE
REITERATEBuy
Aug 6, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.0M
sold · 2 insiders
DateInsiderTypeValue
Jun 30, 2026
Barton Shane
Principal Accounting Officer
Jun 30, 2026
EXERCISE$46.5K
Jun 30, 2026
Barton Shane
Principal Accounting Officer
Jun 30, 2026
SELL$509.2K
Jun 30, 2026
Barton Shane
Principal Accounting Officer
Jun 30, 2026
EXERCISE$33.6K
Jun 30, 2026
Barton Shane
Principal Accounting Officer
Jun 30, 2026
EXERCISE$17.5K
Jun 30, 2026
Barton Shane
Principal Accounting Officer
Jun 30, 2026
EXERCISE$34.4K
Jun 29, 2026
Barton Shane
Principal Accounting Officer
Jun 29, 2026
EXERCISE$100.9K
Jun 29, 2026
Barton Shane
Principal Accounting Officer
Jun 29, 2026
SELL$1.1M
Jun 29, 2026
Barton Shane
Principal Accounting Officer
Jun 29, 2026
EXERCISE$60.9K

Earnings setup

Estimates
Nov 25
reports in 9 days
−$0.73
EPS estimate, this quarter
−16%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.73-$0.79–-$0.67-16.1%$1.0M
Next Q-$0.69-$0.78–-$0.58-22.9%$383.3K
Current FY-$2.57-$2.65–-$2.50-8.2%$6.9M
Next FY-$2.62-$3.12–-$1.93-8.5%$14.5M

Short side

FINRA· Oct 30, 2026
3,725,017
shares short
+8.6%
vs prior settlement
4.3
days to cover
≈8.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 5, 2026 SEC
The company completed enrollment in the QUELL-CV Phase 2 cardiovascular trial with topline data expected in Q4 2026…
8-K · Impact 4/10
Nov 5, 2026 SEC
BioAge reported Q3 2026 net loss of $33.5M ($0.73/share), wider than the $20.2M loss a year ago, as R&D spending…
PRESS-RELEASE · Impact 4/10
Nov 5, 2026 Earnings
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLR
Jun 30, 2026 Insider
Barton Shane acquired via exercise 4,290 shares
Principal Accounting Officer @ $10.85 ($46.5K)
Jun 30, 2026 Insider
Barton Shane sold 20,216 shares
Principal Accounting Officer @ $25.19 ($509.2K)
Jun 30, 2026 Insider
Barton Shane acquired via exercise 4,000 shares
Principal Accounting Officer @ $8.39 ($33.6K)
Jun 30, 2026 Inst.
BlackRock, Inc. · ADD
2,849,077 shares ($69.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent
Nov 5, 2026
Earnings
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline…
Sep 25, 2026
Press release
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology…
Sep 2, 2026
Press release
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology…
Aug 31, 2026
Short interest
Short Interest: BIOA up 23% to 2.7M shares
Settlement 2026-08-31 | Days to cover: 4.72 | ≈5.93% of shares outstanding (est.)
Aug 12, 2026
Earnings date
BIOA Q2 2026 Earnings Scheduled, 2026-08-12

SecBot reports

8 filings · 3 press releases · 3 bullish · 0 bearish · 5 neutral
All BIOA filing & press-release reports (11)